With the introduction of weight loss medications like Wegovy and Saxenda in New Zealand, their effects are becoming increasingly studied. These GLP-1 receptor agonists mimic the gut hormone glucagon-like peptide 1, which aids in digestion, appetite suppression, and insulin release. While they promote weight loss and offer additional health benefits, there are emerging concerns regarding their side effects. Ongoing research continues to investigate the relevance of findings to the specific brands available in New Zealand.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
